Qiagen N.V.
Qiagen N.V. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836). In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $2.1 billion and a profit of $425 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2836, Biological Products, (No Diagnostic Substances)); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.3 out of ten, 8 of 9 metrics filed and 1 estimated: past 7.4 out of ten, present 6.7 out of ten, future 4.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2017. 80th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 6.9 out of ten. +5.1% a year over 10 filed years; profitable in 9 of 10. 69th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 7.3 out of ten. Share count shrank 1.7% a year. 35% of cash flow returned. Insiders: 0 sales, 0 purchases. 73rd percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 7.1 out of ten. ROE 11%: 11¢ of profit per shareholder dollar. Leverage 40%: owes 40¢ per asset dollar. 71st percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.3 out of ten. top 27% of 102 in its family; net margin 20.3%. 73rd percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 130 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
- Room to expand (future): 3.6 out of ten. bottom 36% of 92 in its family for room to expand. 36th percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.5 out of ten. top 45% of 100 in its family for growth drivers. 55th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.7 out of ten. top 43% of 72 in its family for expectations against reality. 57th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-03-20 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-09. Filings on record since 1998. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Diagnostic Solutions 38%, Sample Technologies 32%, PCR Nucleic Acid Amplification 15%, Genomics NGS 12%, Product and Service Other 4%. By geography: United States 47%, Europe, Middle East and Africa 34%, Asia Pacific, Japan and Rest of World 14%, Other Americas 4%, Netherlands 1%. As tagged in its annual report (Form 20-F, filed 2026-03-20).
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.